lovastatin / Generic mfg. - LARVOL DELTA

Real-world impact of lipophilic statins on survival outcomes in polycythemia vera and essential thrombocythemia (ASH 2025) - "Preclinical studies have suggested that lipophilic statins—such as simvastatin, lovastatin, and atorvastatin—may disrupt membrane lipid rafts, thereby interfering with JAK2-V617F–mediated signaling... In this large, real-world cohort study, lipophilic statin use was associated with a significant reduction in all-cause mortality among patients with polycythemia vera or essential thrombocythemia. These findings highlight the potential role of statins as adjunctive therapy in myeloproliferative neoplasms and warrant further prospective evaluation."

Clinical • Real-world • Real-world evidence • Acute Myelogenous Leukemia • Chronic Eosinophilic Leukemia • Essential Thrombocythemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myeloproliferative Neoplasm • Polycythemia Vera • Thrombocytosis

A Horizontally Transferred Alginate Metabolism Gene Cluster in the Human Gut Genus Bacteroides. (PubMed, J Appl Glycosci (1999)) - "In this study, we purified an alginate lyase from enrichment culture supernatants containing alginate, using a human fecal sample, and isolated B. xylanisolvens strain MK6803, which can grow on alginate as a sole carbon source-unlike the type strain B. xylanisolvens XB1A...Phylogenetic analysis indicated horizontal gene transfer within the genus Bacteroides. These findings highlight the role of alginate metabolism in the adaptation of human gut microbiota."

Journal • Gene Therapies

Ribociclib drug-drug interaction and concomitant medication management in early and advanced breast cancer patients (SABCS 2025) - "Background: Ribociclib is approved for the treatment of HR+/HER2- advanced or metastatic breast cancer (ABC) in combination with an aromatase inhibitor or fulvestrant, and more recently, for the adjuvant treatment of HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence, with the starting dose of 600 mg in ABC and 400mg in EBC...The effect of ribociclib on rosuvastatin, pravastatin, pitavastatin, and fluvastatin is considered minor with no clinical relevance, since these statins are not sensitive CYP3A4 substrates...No clinically relevant DDI is expected for commonly used antidepressants/antipsychotics, such as citalopram, escitalopram, fluoxetine, mirtazapine, sertraline, trazodone, venlafaxine, aripiprazole, olanzapine and cariprazine, when co-administered with ribociclib 400 mg or 600 mg... No clinically relevant DDI with ribocicilib is anticipated for commonly used statins or antidepressants/antipsychotics, except simvastatin, lovastatin,..."

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Combination of ALK2 and cholesterol targeting agents exploits linked genetic and metabolic dependencies in diffuse midline glioma (SNO 2025) - "Drug-combination screens identified clinically well-tolerated statins, including simvastatin/lovastatin which target the rate-limiting cholesterol synthesis enzyme HMG-CoA reductase, and estrogen receptor inhibitors, including Tamoxifen, which exhibits off-target effects on EBP, as sensitisers to ALK2i...Forced differentiation of DMG cells to an astrocyte-like cell state increased cholesterol production and led to a significant decrease in M4K2009 sensitivity and synergy with statins, which was phenocopied when DMG cells were co-cultured with normal astrocytes. This was overcome in vitro, ex vivo and in vivo using a triple combination including a LXR agonist (LXR623) to promote cholesterol export. We identify a previously unappreciated link between ALK2 signalling and cholesterol homeostasis which may be exploited clinically by combining ALK2i with routinely-used statins and BBB-penetrant LXR agonists."

Brain Cancer • Diffuse Midline Glioma • Glioma • Solid Tumor • ABCA1 • ACVR1 • SREBF2

Mevinolin (MEV) modulates terpenoid biosynthesis in 'Shine Muscat' grapes by regulating HMGR enzyme. (PubMed, BMC Plant Biol) - "Notably, G8H was negatively correlated with most genes and metabolites. Overall, these findings demonstrate that MEV substantially influences terpenoid biosynthesis and metabolism in "Shine Muscat" grape fruits."

Journal

Polyphyllin H Reverses Paclitaxel Resistance in Breast Cancer by Binding Membrane Cholesterol to Inhibit Both ABCB1 and ABCC3. (PubMed, Pharmaceuticals (Basel)) - " PPH reverses PTX resistance by targeting cholesterol-lipid rafts to inhibit multiple ABC transporters. This offers a safer adjuvant for PTX-based breast cancer therapy and a translational framework for other drug-resistant malignancies."

Journal • Breast Cancer • Oncology • Solid Tumor • ABCB1 • ABCC3

Lipid-Lowering Therapy Is Underutilized Across LDL-C Levels in Autoimmune Disease Compared to Diabetes: A Nationwide Analysis (AHA 2025) - "Statins included atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin. Non-statin therapies included icosapent ethyl, colesevelam, alirocumab, evolocumab, Bempedoic acid, cholestyramine, Inclisiran, colestipol, ezetimibe, gemfibrozil, omega-3 acid, fenofibrate...Non-statin lipid-lowering therapy use was significantly lower in autoimmune patients compared to those with diabetes across all LDL-C tertiles, with the largest differences observed at LDL <70 mg/dL (6.19% vs 10.24%, p<0.0001) and 70–99 mg/dL (4.05% vs 7.06%, p<0.0001).ConclusionDespite comparable ASCVD risk, patients with autoimmune disease are significantly less likely to receive statins or non-statin lipid-lowering therapy than those with DM across LDL-C levels. These findings show a need for improved cardiovascular prevention in this high-risk population."

Atherosclerosis • Cardiovascular • Diabetes • Dyslipidemia • Hepatology • Immunology • Inflammatory Arthritis • Lupus • Metabolic Disorders • Rheumatoid Arthritis • Rheumatology • Systemic Lupus Erythematosus

Combination of ALK2 and cholesterol targeting agents exploits linked genetic and metabolic dependencies in diffuse midline glioma (WFNOS 2025) - P1 | "Drug-combination screens identified clinically well-tolerated statins, including simvastatin/lovastatin which target the rate-limiting cholesterol synthesis enzyme HMG-CoA reductase, and estrogen receptor inhibitors, including Tamoxifen, which exhibits off-target effects on EBP, as sensitisers to ALK2i...Forced differentiation of DMG cells to an astrocyte-like cell state increased cholesterol production and led to a significant decrease in M4K2009 sensitivity and synergy with statins, which was phenocopied when DMG cells were co-cultured with normal astrocytes. This was overcome in vitro, ex vivo and in vivo using a triple combination including a LXR agonist (LXR623) to promote cholesterol export. We identify a previously unappreciated link between ALK2 signalling and cholesterol homeostasis which may be exploited clinically by combining ALK2i with routinely-used statins and BBB-penetrant LXR agonists."

Brain Cancer • Diffuse Midline Glioma • Glioma • Solid Tumor • ABCA1 • ACVR1 • SREBF2

Lovastatin-Loaded Nanoparticles in a Thermosensitive Chitosan Hydrogel as a Sustained Release System for Treating Intervertebral Disc Degeneration: In Vitro Cell Culture Study and In Vivo Evaluation Using a Needle-Puncture Induced Degeneration Model in Rat Caudal Discs. (PubMed, JOR Spine) - "LVS-NPs demonstrated sustained release of lovastatin and extended stimulatory effects on human nucleus pulposus cells in vitro. However, further research is needed to optimize the hydrogel volume and its ratio to intradiscal space and increase lovastatin concentration within LVS-NPs to achieve optimal therapeutic outcomes while minimizing mechanical compression to surrounding tissues."

Journal • Preclinical • Fibrosis • ACAN

Cholesterol-lowering statin drugs reduce metastatic potential of renal cancer (EMUC 2025) - "Unraveling the mechanism of the effects of older statins may provide new treatment targets for RCC. This area of investigation might hold promise for developing statin derivatives to prevent metastatic spread of RCC."

Metastases • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Urethral Cancer • VHL

Targeting Cholesterol Homeostasis Enhances Phagocytosis of Acute Myeloid Leukemia Cells (ASH 2024) - "Pharmacological inhibition of cholesterol synthesis by Lovastatin results in enhanced phagocytosis of AML cells. These findings reveal cholesterol homeostasis as a novel dependency of AML cells, findings that may translate into new therapeutic opportunities."

Acute Myelogenous Leukemia • Cholera • Hematological Malignancies • Leukemia • Oncology • Pediatrics • CAV2 • CD34 • HLA-A • LRP4 • MFSD2A

Computational Evaluation of Statin Analogs Targeting HMG-CoA Reductase for Coronary Artery Disease Treatment. (PubMed, ChemistryOpen) - "ADMET analysis showed that analogs of simvastatin, lovastatin, and pravastatin have favorable pharmacological profiles and low toxicity...This ligand-induced rigidity is a powerful indicator of enhanced inhibitory efficacy and stability. Our findings highlight that statin analogs are a promising class whose unique binding dynamics offer a new, rational pathway for designing more effective HMG-CoA reductase inhibitors."

Journal • Cardiovascular • Coronary Artery Disease

Turmeric, Red Yeast Paste, and Statins: A Recipe for DILI (ACG 2025) - "Spironolactone helped reduce swelling. This is a case of new onset hepatocellular pattern (R factor 7.4) acute liver injury without past chronic hepatic disease. Red yeast is a traditional Chinese herbal remedy containing monacolin K, an identical agent to lovastatin. Prospective controlled studies do not show a significant enzyme increase in LFTs, but there are isolated case reports with liver injury second to consumption of red yeast."

Hepatology • Infectious Disease • Inflammation • Liver Failure

A Glycerophospholipid Metabolism-Based Prognostic Model Guides Osteosarcoma Therapy. (PubMed, Transl Oncol) - "GAS-based stratification not only robustly predicts OS prognosis but also reveals interactions between glycerophospholipid metabolism and tumor immunity, guiding personalized therapeutic strategies and highlighting novel drug candidates for high-risk patients."

IO biomarker • Journal • Metabolic Disorders • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

The effects and potential mechanisms of statins on growth, development and pathogenicity in Botrytis cinerea. (PubMed, World J Microbiol Biotechnol) - "Fluvastatin, atorvastatin, simvastatin and lovastatin strongly suppressed hyphal growth of B. cinerea, with EC50 values of 0.66, 3.0, 10.0 and 22.21 µg/mL respectively...We demonstrated that statins exert inhibitory effects on mycelial growth, development and pathogenicity of B. cinerea, with HMGR predicted as the molecular target. These findings collectively indicated that HMGR was a potential novel control target and statins could be used as lead compounds for developing novel agents."

Journal • Infectious Disease

Development and Application of an Algorithm for Statin-Induced Myopathy Based on Electronic Health Record-Derived Structured Elements. (PubMed, Pharmacoepidemiol Drug Saf) - "We have produced an efficient, easy-to-apply methodological tool that can improve the quality of future research on SIM."

Journal • Endocrine Disorders • Myositis

Statin induces epithelial cell death and tissue barrier damage in renal tubule on chip. (PubMed, Toxicology) - "Different from what we expected, lovastatin-treated epithelial cells exhibited exacerbated tubular injury and further increased ROS production following the addition of N-acetylcysteine or GSH...These findings demonstrate that lovastatin induces oxidative stress via GSH, with ROS-mediated pathways driving tubular injury. This study establishes a platform for the in vitro assessment of drug cytotoxicity and the investigation of statin-related renal side effects."

Journal

Mechanistic Insights into Cytokinin-Regulated Leaf Senescence in Barley: Genotype-Specific Responses in Physiology and Protein Stability. (PubMed, Int J Mol Sci) - "Collectively, these findings identify Bursztyn as a novel genetic resource for stay-green traits and demonstrate that BA delays DIS primarily by maintaining photosynthetic integrity and redox balance. The results highlight distinct regulatory networks shaping CK-mediated senescence responses in cereals, with implications for improving stress resilience and yield stability."

Journal • Targeted Protein Degradation

Cytokinin-induced phenotypic and endogenous phytohormonal dynamics during potato (Solanum tuberosum L.) tuber development in vitro. (PubMed, J Plant Physiol) - "Inhibition of CK biosynthesis elicited changes in CKs, JAs, and ABA levels, as well as in the associated phytohormone ratios, that were opposite to those observed with 0.1 μM 2ip treatment. Thus this study revealed the specific physiological roles of active CKs in tuber development and provided insights into the mechanisms of tuber development regulated by CKs."

Journal • Preclinical

A 48-bp deletion within the promoter of the BnaC9.APT5 gene results in elevated seed number per silique in Brassica napus. (PubMed, New Phytol) - "A 48-bp InDel in the BnaC9.APT5 promoter was significantly associated with gene expression and SNPS and has been selected during rapeseed 'double-low' quality breeding. Our data provide clear evidence of the role of the BnaC9.APT5 gene for the genetic improvement of modern rapeseed."

Journal

Pigment Formation by Monascus pilosus DBM 4361 in Submerged Liquid Culture. (PubMed, J Agric Food Chem) - "Monascus pilosus is usually cultivated on rice because of monacolin K. We focused on pigment production in submerged liquid culture (SLC) where M. pilosus produced different pigments compared to M. purpureus and M. ruber...In SLC, previously undescribed patterns affecting pigment formation were observed, such as the Crabtree effect, carbon catabolite repression of pigments caused by glucose and other mono-/disaccharides, as well as nitrogen regulation, particularly repression of pigment formation by ammonium sulfate. The highest pigment concentration in the extract was obtained using an organic nitrogen source, specifically 340 mg/L for yellow pigments utilizing a combination of sucrose and tryptone, 346 mg/L for orange pigments using starch and tryptone, and 75 mg/L for red pigments using lactose and tryptone."

Journal

PRESCRIBING PATTERNS OF STATINS IN DECOMPENSATED CIRRHOSIS: A MULTI-CENTER COHORT STUDY (AASLD 2025) - "Atorvastatin was the most commonly used (50.9%), followed by simvastatin (24.2%), pravastatin (12.3%), rosuvastatin (10.1%), lovastatin (2.2%), and pitavastatin (0.4%) (p < 0.001)... Statins are actively prescribed in patients with decompensated cirrhosis awaiting transplantation, despite prior concerns about hepatotoxicity. The clear predominance of lipophilic statins reflects existing evidence supporting their potential benefits in cirrhosis. These findings emphasize the need for prospective studies to better define the optimal statin type and dosage in this high-risk population."

Clinical • Fibrosis • Hepatology • Immunology • Liver Failure • Solid Organ Transplantation

REAL-WORLD IMPLICATIONS OF THE NEW AASLD/IDSA HCV "TEST AND TREAT" ALGORITHM: FOCUS ON CARDIOVASCULAR COMEDICATIONS IN HEPATITIS C VIRUS (HCV) PATIENTS RECEIVING DIRECT-ACTING ANTIVIRALS (DAAS) (AASLD 2025) - " We leveraged the IQVIA PharMetrics Plus claims database (July 2015-June 2023) to evaluate the co-administration of statins and antihypertensive drugs with pDAAs, specifically sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB), in US patients...All 321 contraindications among statin users were associated with GLE/PIB, specifically involving atorvastatin, lovastatin, and simvastatin. For antihypertensives, olmesartan, prazosin, and enalapril were the most common comedications posing a clinically significant DDI risk. Applying the new AASLD/IDSA algorithm, especially when statins or antihypertensives are co-administered with pDAAs, would necessitate specialist consultation for a significant number of patients due to DDI risk. This potential barrier to rapid "test and treat" implementation could be substantially reduced by carefully selecting the DAA regimen based on individual patient DDI risk profiles."

Clinical • Real-world • Real-world evidence • Cardiovascular • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Dual modulation of lipid and glucose metabolism by a nutraceutical combination in patients at cardiometabolic risk: results from a multicenter randomized controlled trial. (PubMed, Cardiovasc Diabetol) - P=N/A | "Taken together, our findings indicate that the treatment with a NUT combination containing Morus alba simultaneously reduces plasma levels of LDL-C and glucose."

Journal • Cardiovascular • Hypertension • Metabolic Disorders

Safety and Efficacy of Moderate vs High Intensity Statin Therapy After Nontraumatic Intracerebral Hemorrhage: A Real-World Evidence Analysis. (PubMed, Cerebrovasc Dis) - "In this large, real-world analysis, moderate-intensity statins demonstrated statistically significant but modest reductions in recurrent ICH, ischemic stroke, composite vascular events, and all-cause mortality compared with high-intensity statins, without increased adverse events. These findings may support preferential use of moderate-intensity statin therapy in selected post-ICH patients pending confirmation from randomized trials. While these observational findings suggest potential benefits of moderate-intensity statin therapy in selected post-ICH patients, confirmation from randomized controlled trials is needed before definitive clinical recommendations can be made."

HEOR • Journal • Real-world evidence • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • Hepatology • Ischemic stroke • Liver Failure